Game plan confirmed, page-31

There are quite a few things to consider here . (1) The TAVR market has more than doubled since the Corevalve deal was done in 2008 . (2) AVR s. TAVR appears to be substaintialy better than anything on the market (3) The deal is probably going in include the ADAPT IP and tech along with projects already on the drawing board . (4) Corevales TAVR did not have anywhere near the data nor did it have FDA approval at the time of purchase . As far as what the deal is worth ? One would have to assume at least double the 2008 figure paid for Corevalve . By virtue of the fact there could be multipull companies in the game here something that was not the case with the Corevalve acquisition it’s hard to say where it could end up . And no I have not spoken with the company or WP I just use logic .